Literature DB >> 15053822

Increased susceptibility of ventricular arrhythmias to aconitine in anaesthetized rats is attributed to the inhibition of baroreflex.

He Shu1, Wuliya Yi-Ming, Li-Ping Xu, Chao-Yu Miao, Ding-Feng Su.   

Abstract

1. Aconitine is widely used to produce ventricular arrhythmias in anaesthetized rats. The present work was designed to test the hypothesis that anaesthesia may increase the susceptibility of ventricular arrhythmia to aconitine due to the inhibition of arterial baroreflex. In addition, the susceptibility of ventricular arrhythmia to aconitine at different times during the course of a whole day was also investigated. 2. Male Sprague-Dawley rats were used. Arrhthymias were induced by aconitine infusion at six time points (01.00, 05.00, 09.00, 13.00, 17.00 and 21.00 h) with rats in both anaesthetized and conscious states. In sinoaortic-denervated (SAD) rats, ventricular arrhythmias were induced by aconitine infusion between 09.00 and 13.00 h. 3. There was a significant difference in the lethal dose of aconitine between anaesthetized and conscious rats (99.6 +/- 30.1 vs 58.2 +/- 14.7 micro g/kg; P < 0.001). Anaesthesia did increase the susceptibility of rats to ventricular arrhythmias following aconitine. 4. In SAD rats, the lethal dose of aconitine was less than that for baroreflex-intact rats when determined in the conscious state. The difference in the lethal dose of aconitine between SAD and baroreflex-intact rats disappeared when it was determined in anaesthetized rats. 5. The time of day did not affect the susceptibility of either anaesthetized or conscious rats to ventricular arrhythmias following aconitine, except for a difference in the ventricullar fibrillation threshold dose between 13.00 and 17.00 h in anaesthetized rats. 6. In conclusion, anaesthesia may increase the risk of ventricular arrhythmias following aconitine. Intact arterial baroreflex function is necessary to prevent drug-induced ventricular arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15053822     DOI: 10.1111/j.1440-1681.2004.03988.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  7 in total

1.  Autonomic and cellular mechanisms mediating detrimental cardiac effects of status epilepticus.

Authors:  Steven L Bealer; Jason G Little; Cameron S Metcalf; Amy L Brewster; Anne E Anderson
Journal:  Epilepsy Res       Date:  2010-07-21       Impact factor: 3.045

2.  Strain differences in baroceptor reflex in adult Wistar Kyoto rats.

Authors:  Vitor E Valenti; Luiz Carlos de Abreu; Caio Imaizumi; Márcio Petenusso; Celso Ferreira
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

3.  Biological Evaluation of Polyherbal Ayurvedic Cardiotonic Preparation "Mahamrutyunjaya rasa".

Authors:  Pallavi D Rai; Sadhana J Rajput
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-02       Impact factor: 2.629

4.  Metabolic syndrome emerges after artificial selection for low baroreflex sensitivity.

Authors:  Li-Li Zhang; Ying Zhang; Yan-Qiong Cheng; Jing-Ming Zhang; Hong-Qi Liu; Wei-Zhong Wang; Jawahar L Mehta; Zhi-Gang Xiong; Ding-Feng Su; Ai-Jun Liu
Journal:  CNS Neurosci Ther       Date:  2018-07-01       Impact factor: 5.243

5.  Baroreflex sensitivity differs among same strain Wistar rats from the same laboratory.

Authors:  Vitor E Valenti; Luiz Carlos de Abreu; Hugo Macedo Junior; Oseas F Moura Filho; Celso Ferreira
Journal:  Heart Int       Date:  2011-10-21

6.  The variability of baroreflex sensitivity in juvenile, spontaneously hypertensive rats.

Authors:  V E Valenti; L C De Abreu; E Colombari; M A Sato; C Ferreira
Journal:  Cardiovasc J Afr       Date:  2011 Jan-Feb       Impact factor: 1.167

Review 7.  Relationships between the Toxicities of Radix Aconiti Lateralis Preparata (Fuzi) and the Toxicokinetics of Its Main Diester-Diterpenoid Alkaloids.

Authors:  Mengbi Yang; Xiaoyu Ji; Zhong Zuo
Journal:  Toxins (Basel)       Date:  2018-09-26       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.